🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Health Concern

The sexually transmitted infection are on the rise globally, with data suggesting in excess of 82 million new cases per year. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Receive Authorization

Zoliflodacin, marketed under the name a brand name, was cleared by the US FDA in mid-December for use against gonorrhoea. This STI can lead to significant complications, including infertility. Experts believe that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in the same week. This medication, which is employed against UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a unique collaborative effort for drug creation. The non-profit organisation GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This approval marks a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Outcomes and Global Access

As per findings detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of cases of the STI. This places it at an comparable level with the current standard treatment, which combines two antibiotics. The study enrolled nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Doctors treating patients have voiced hope. Access to a single-dose, oral treatment such as this is hailed as a "revolutionary step" for gonorrhoea control. This is considered essential to reduce the burden of the disease for people and to prevent the spread of untreatable gonorrhoea globally.